• Professional Development
  • Medicine & Nursing
  • Arts & Crafts
  • Health & Wellbeing
  • Personal Development

222 Educators providing Courses

London Biokinetics

london biokinetics

London

A Biokineticist is a clinical exercise specialist who: Functions within professional alliance to health and medicine. Improves a person’s physical well-being and quality of life through individualised scientific assessment and the prescription of exercise in rehabilitative treatment to prevent or intervene with certain ailments and the enhancement of performance (sport and work). Evaluates & Measures: body posture, body composition, blood pressure, glucose levels, lung function, heart rate, fitness, muscle strength, endurance, power, flexibility and other health screenings. Is a health professional who through health promotion and wellness create a better quality of life for people they work with. Movement is an essential part of everyday life, for people of all ages. Movement affects development, learning, communicating, work capacity, health, and quality of life. Movement permits people to navigate and stay oriented within their environment. It allows people to interact more fully in their work and recreation. It is a defining element of quality of life. Movement may be diminished or lost due to heredity, ageing, injury, or disease. Such loss may occur gradually, over the course of a lifetime, or traumatically in an instant. Conditions of movement loss that are linked with chronic and disabling diseases pose additional challenges for patients and their families. From the public health perspective, the prevention of either the initial impairment, or additional impairment from this environmentally orienting and socially connecting functioning, requires significant resources. Prevention of movement loss or the resulting disabling conditions, through the development of improved disease prevention, detection, or treatment methods or more effective rehabilitative strategies, must be a global priority. The profession of Biokinetics has evolved as a primary care health profession responding to the universal need for quality, accessible, cost-effective health care. Biokineticists are widely distributed in communities around the world. They provide economic value for the services they offer, they detect a wide spectrum of conditions at a savings to the health care system, they provide entry into the health care system for many patients who would otherwise not seek care, and they promote quality of life and individual independence, rather than more costly institutionalized and supported care.

Pcsk9 Education And Research Forum

pcsk9 education and research forum

Alcester

Reducing low density lipoprotein (LDL) cholesterol is the priority in managing patients with severe dyslipidaemia (cholesterol abnormality) and at high risk of cardiovascular (CV) death and disability. Yet even when treated with potent statins, many patients fail to achieve LDL-cholesterol targets and therefore their risk of accelerated atherosclerosis and CV death remains high. This problem is particularly critical in patients with familial hypercholesterolaemia (FH) (the most commonly occurring genetic condition in the world). People with FH typically have very high LDL cholesterol levels on treatment, and consequently, are at very high risk of premature and sudden CV death, myocardial infarction and stroke. Additionally, some patients are unable to tolerate statins – particularly at higher doses – and, therefore, do not achieve LDL-cholesterol goals. What is the importance of PCSK9? Discovered in 2003,1 PCSK9 is a protein made by the liver which increases the removal of LDL receptors from the surface of liver cells. These LDL receptors are critically important in removal of serum LDL-cholesterol from the circulation. People with so-called ‘gain of function’ PCSK9 mutations over-express PCSK9, and therefore have very high plasma levels of LDL cholesterol and are at very risk of atherosclerosis and CV mortality and morbidity.2 In contrast, people with so-called ‘loss of function’ PCSK9 mutations, have very LDL cholesterol levels and reduced risk for heart disease.3 What is PCSK9 inhibition? Different approaches to lowering PCSK9 are now licensed. These include fully human monoclonal antibodies (alirocumab, evolocumab) and a small-interfering RNA therapy (inclisiran). Trials show that these PCSK9 inhibitors reduce LDL cholesterol levels by about 50-60 percent - a significantly greater effect than that achieved with currently available therapies – either when given alone or in combination. These LDL cholesterol lowering effects have been consistently across a broad group of patients, including those with familial hypercholesterolaemia in clinical trials.4 Which clinical settings will benefit from the availability of PCSK9 inhibitors? These treatments offer the potential to reduce cardiovascular risk in patients whose clinical needs cannot be satisfied by current therapy. These include: Patients with familial hypercholesterolaemia – an inherited disorder of lipid metabolism with a very high risk of early CV death or morbidity, if not diagnosed or treated early Patients who cannot tolerate statins, who therefore remain at high risk of CV events such as heart attacks and strokes Patients with established heart disease who have not achieved LDL-cholesterol goals despite current therapies